ArticleMolecular therapy oncolytics2022

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.

Chris Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.